| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | PG-110: A Bi-Specific ActRII/Myostatin Blocker for Metabolic and Musculoskeletal Health | ||||||
| Antibody | Obesity | ActRII/Myostatin | Lead | ProGen Co., Ltd. | RS-2025-02213767 | ||
| 2 | A Study on the Hit to Lead Optimization of Resistin Targeting Antibodies as a Treatment for Non-Alcoholic Fatty Liver Disease | ||||||
| Antibody | NASH | Resistin, CAP1 | Lead | Seoul National University Hospital | HN21C0524 | ||